Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Controller Medication
100%
Asthma Exacerbation
100%
Long-term Clinical Study
100%
Odds Ratio
75%
Montelukast
75%
Persistent Asthma
75%
Moderate to Severe
50%
Peak Expiratory Flow
50%
Monotherapy
50%
Twice Daily
50%
Fluticasone Propionate
50%
Controller
25%
Multivariate Analysis
25%
Child Age
25%
Once-daily
25%
Inhaled Corticosteroids
25%
Positive Predictive Value
25%
Critical Illness
25%
Common Cause
25%
Regression Modeling
25%
Salmeterol
25%
Hospital Care
25%
Physiological Measurement
25%
Pediatric Asthma
25%
Exacerbation Risk
25%
Study within a Trial
25%
Inflammatory Parameters
25%
Emergency Care
25%
Diary Card
25%
Controller Treatment
25%
Oral Corticosteroids
25%
Pulmonary Function Parameters
25%
Demographic Parameters
25%
Physiological Biomarkers
25%
Time Factors
25%
Systemic Corticosteroids
25%
Lower Peak
25%
Medicine and Dentistry
Clinical Trial
100%
Asthma Exacerbation
100%
Montelukast
75%
Odds Ratio
75%
Peak Expiratory Flow
50%
Asthma
50%
Monotherapy
50%
Moderate Persistent Asthma
50%
Corticosteroid
50%
Biological Marker
25%
Pediatrics
25%
Critical Illness
25%
Hospital Care
25%
Salmeterol
25%
Fluticasone
25%
Fluticasone Propionate
25%
Oral
25%
Multivariate Analysis
25%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Asthma
100%
Montelukast
50%
Monotherapy
33%
Moderate Persistent Asthma
33%
Corticosteroid
33%
Biological Marker
16%
Critical Illness
16%
Salmeterol
16%
Fluticasone Propionate
16%
Fluticasone
16%
Neuroscience
Montelukast
100%
Corticosteroid
66%
Peak Expiratory Flow
66%
Agonist
33%
Fluticasone Propionate
33%
Fluticasone
33%
Salmeterol
33%
Pediatrics
33%
Biological Marker
33%
Immunology and Microbiology
Asthma Exacerbation
100%
Montelukast
75%
Asthma
50%
Peak Expiratory Flow
50%
Moderate Persistent Asthma
50%
Agonist
25%
Salmeterol
25%
Fluticasone
25%
Fluticasone Propionate
25%